FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Lai, FTT
   Huang, L
   Chui, CSL
   Wan, EYF
   Li, X
   Wong, CKH
   Chan, EWW
   Ma, TT
   Lum, DH
   Leung, JCN
   Luo, H
   Chan, EWY
   Wong, ICK
AF Lai, Francisco Tsz Tsun
   Huang, Lei
   Chui, Celine Sze Ling
   Wan, Eric Yuk Fai
   Li, Xue
   Wong, Carlos King Ho
   Chan, Edward Wai Wa
   Ma, Tiantian
   Lum, Dawn Hei
   Leung, Janice Ching Nam
   Luo, Hao
   Chan, Esther Wai Yin
   Wong, Ian Chi Kei
TI Multimorbidity and adverse events of special interest associated with
   Covid-19 vaccines in Hong Kong
SO NATURE COMMUNICATIONS
LA English
DT Article
ID VACCINATION; CARE
AB Prior research using electronic health records for Covid-19 vaccine safety monitoring typically focuses on specific disease groups and excludes individuals with multimorbidity, defined as >= 2 chronic conditions. We examine the potential additional risk of adverse events 28 days after the first dose of CoronaVac or Comirnaty imposed by multimorbidity. Using a territory-wide public healthcare database with population-based vaccination records in Hong Kong, we analyze a retrospective cohort of patients with chronic conditions. Thirty adverse events of special interest according to the World Health Organization are examined. In total, 883,416 patients are included and 2,807 (0.3%) develop adverse events. Results suggest vaccinated patients have lower risks of adverse events than unvaccinated individuals, multimorbidity is associated with increased risks regardless of vaccination, and the association of vaccination with adverse events is not modified by multimorbidity. To conclude, we find no evidence that multimorbidity imposes extra risks of adverse events following Covid-19 vaccination.
   Adverse events resulting from COVID-19 vaccination are a public health concern and it is not known whether pre-existing conditions may impose an increased risk. Here, using electronic health records from Hong Kong, the authors show that adverse events are rare for all groups, and there is no evidence of risk modification due to multimorbidity.
C1 [Lai, Francisco Tsz Tsun; Huang, Lei; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Chan, Edward Wai Wa; Ma, Tiantian; Lum, Dawn Hei; Leung, Janice Ching Nam; Chan, Esther Wai Yin; Wong, Ian Chi Kei] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China.
   [Lai, Francisco Tsz Tsun; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Li, Xue; Wong, Carlos King Ho; Ma, Tiantian; Leung, Janice Ching Nam; Chan, Esther Wai Yin; Wong, Ian Chi Kei] Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth D24H, Hong Kong Sci Pk, Hong Kong, Peoples R China.
   [Chui, Celine Sze Ling] Univ Hong Kong, Li Ka Shing Fac Med, Sch Nursing, Hong Kong, Peoples R China.
   [Chui, Celine Sze Ling] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China.
   [Wan, Eric Yuk Fai; Wong, Carlos King Ho] Univ Hong Kong, Li Ka Shing Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China.
   [Li, Xue] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China.
   [Luo, Hao] Univ Hong Kong, Fac Social Sci, Dept Social Work & Social Adm, Hong Kong, Peoples R China.
   [Luo, Hao] Univ Hong Kong, Fac Engn, Dept Comp Sci, Hong Kong, Peoples R China.
   [Wong, Ian Chi Kei] UCL, Sch Pharm, Res Dept Practice & Policy, London, England.
RP Wong, ICK (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China.; Wong, ICK (corresponding author), Hong Kong Sci & Technol Pk, Lab Data Discovery Hlth D24H, Hong Kong Sci Pk, Hong Kong, Peoples R China.; Wong, ICK (corresponding author), UCL, Sch Pharm, Res Dept Practice & Policy, London, England.
EM wongick@hku.hk
RI Lai, Francisco TT/F-3842-2019; Wong, Carlos King-ho/B-4322-2011
OI Lai, Francisco TT/0000-0002-9121-1959; Wong, Carlos
   King-ho/0000-0002-6895-6071
FU Food and Health Bureau, Government of the Hong Kong Special
   Administrative Region of China [COVID19F01]
FX This study was funded by a research grant from the Food and Health
   Bureau, Government of the Hong Kong Special Administrative Region of
   China to Prof. Ian Chi Kei Wong (reference COVID19F01). We thank Mr.
   Joseph Blais for language proofreading this manuscript.
CR Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475
   Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2
   Brilleman SL, 2013, FAM PRACT, V30, P172, DOI 10.1093/fampra/cms060
   Calderon-Larranaga A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X659295
   Centre for Health Protection, INT GUID NOT COMM ME
   Centre for Health Protection, HONG KONG VACC DASHB
   Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546
   Chung GKK, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158168
   Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765
   de Simone G, 2021, EUR HEART J-CARD PHA, V7, pE77, DOI 10.1093/ehjcvp/pvab036
   Hanlon P, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018404
   Hong Kong Government, COVID 19 VACC PROGR
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Incalzi RA, 2021, VACCINE, V39, P2325, DOI 10.1016/j.vaccine.2021.03.066
   Kwok KO, 2021, EMERG INFECT DIS, V27, P1802, DOI 10.3201/eid2707.210054
   Lai FTT, 2022, PSYCHOL MED, V52, P283, DOI 10.1017/S0033291720001920
   Lai FTT, 2019, EUR J INTERN MED, V61, P103, DOI 10.1016/j.ejim.2018.12.001
   Lau WCY, 2017, JAMA-J AM MED ASSOC, V317, P1151, DOI 10.1001/jama.2017.1363
   Leung GM, 2009, HEALTH ECON, V18, P37, DOI 10.1002/hec.1342
   Li X., ANN RHEUM DIS, DOI [10.1136/annrheumdis-2021-221571(2021), DOI 10.1136/ANNRHEUMDIS-2021-221571(2021)]
   Li XT, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1435
   Man KKC, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2350
   Marengoni A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1059
   Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8
   Montgomery J, 2021, JAMA CARDIOL, V6, P1202, DOI 10.1001/jamacardio.2021.2833
   Nguyen Hai, 2019, J Comorb, V9, p2235042X19870934, DOI 10.1177/2235042X19870934
   Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5
   Patone M, 2021, NAT MED, V27, P2144, DOI 10.1038/s41591-021-01556-7
   Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577
   Revon-Riviere G, 2021, EUR J CANCER, V154, P30, DOI 10.1016/j.ejca.2021.06.002
   Salah HM, 2021, AM J CARDIOL, V157, P146, DOI 10.1016/j.amjcard.2021.07.009
   Sturkenboom M, COVERAGE COVID 19 VA
   Su S, 2021, NAT REV MICROBIOL, V19, P211, DOI 10.1038/s41579-020-00462-y
   Takuva S, 2021, NEW ENGL J MED, V385, P570, DOI 10.1056/NEJMc2107920
   Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X
   Tonelli M, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0155-5
   Tsai R., JMIR PUBLIC HLTH SUR, DOI [10.2196/29872(2021, DOI 10.2196/29872(2021]
   Wang JT, 2021, J HEPATOL, V75, P439, DOI 10.1016/j.jhep.2021.04.026
   Wong AYS, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.h6926
   World Health Organization, 2020, BACKGR PAP COV 19 DI
   Wu QH, 2021, BMC MED, V19, DOI 10.1186/s12916-021-02059-5
   Yeoh EK, 2020, HEALTH POLICY, V124, P189, DOI 10.1016/j.healthpol.2019.12.009
   Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344
   Zhao QY, 2017, J CAUSAL INFERENCE, V5, DOI 10.1515/jci-2016-0010
NR 44
TC 5
Z9 5
U1 3
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 20
PY 2022
VL 13
IS 1
AR 411
DI 10.1038/s41467-022-28068-3
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YK8QB
UT WOS:000745469500002
PM 35058463
OA Green Published, gold
DA 2022-05-16
ER

EF